Lisa Musick

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Laurie H. Sehn, Mark Hertzberg, Stephen Opat et al. · Blood Advances · 2021 · 169 citations · Full text

R/r Dlbcl, Immunology, Pathology +18

Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant

Janel Long-Boyle, Rada Savic, Shirley Qiong Yan et al. · Therapeutic Drug Monitoring · 2014 · 81 citations · Full text

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

Jason Law, Morton J. Cowan, Christopher C. Dvorak et al. · Biology of Blood and Marrow Transplantation · 2012 · 52 citations · Full text

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA

Alex F. Herrera, Samuel Tracy, Brandon Croft et al. · Blood Advances · 2022 · 32 citations · Full text

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Catherine Diefenbach, Brad S. Kahl, Andrew McMillan et al. · The Lancet Haematology · 2021 · 30 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8